Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer

Anti-Cancer Drugs

Volumn 16, Issue 9, 2005, Pages 1029-1036

  Rademaker Lakhai, Jeany M ^a,b   Crul, Mirjam ^a,b   Pluim, Dick ^a   Sparidans, Rolf W ^c   Baas, Paul ^a   Beijnen, Jos H ^a,b,c   Van Zandwijk, Nico ^a   Schellens, Jan H M ^a,b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Adverse events; Cisplatin; Dose intensity; Gemcitabine; Maximum tolerated dose; Pharmacokinetics

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PLASMA HALF LIFE; PRIORITY JOURNAL; TINNITUS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOXURIDINE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; PLATINUM; TREATMENT OUTCOME;

EID: 26244461247     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000176507.78928.4d     Document Type: Article

References (32)

1. Bulzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM Classification. Cancer 1992; 70:1102-1110.
2. Belani CP. Chemotherapy regimens in advanced non-small cell lung cancer: recent randomized trials. Clin Lung Cancer 2000; 2:S7-S10.
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in NSCLC: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311:899-909.
4. Schiller JH, Harrington D, Sandler A. Randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2000; 19:1a (abstr 2).
5. Crino L, Scagliotti V, Ricci S, De Marinis F, Rinaldi M, Gridelli C, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer: a randomized phase III study of the Italian lung cancer project. J Clin Oncol 1999; 17:3522-3530.
6. Sandler AB, Nemunattis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000; 18:122-130.
7. Sweeney CJ, Sandler AB. Chemotherapy in non-small cell lung cancer. Invest New Drugs 2000; 18:157-186.
8. Manegold C, Zatloukal P, Krejcy K, Blatter J. Gemcitabine in non-small cell lung cancer (NSCLC). Invest New Drugs 2000; 18:29-42.
9. Soto Parra H, Cavina R, Latteri F, et al. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol 2002; 13:1080-1086.
10. Neijt JP, ten Bokkel Huinink WW, Van der Burg ME, van Oosterom AT, Willemse PH, Vermorken JB, et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27:1367-1372.
11. Al-Sarraf M. Head and neck cancer: chemotherapy concepts. Semin Oncol 1988; 15:70-85.
12. Fichtinger-Schepman AM, Van der Veer JL, den Hartog JH, Lohman PH, Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 1985; 24:707-713.
13. Van Moorsel CJA, Peters GJ, Pinedo HM. Gemcitabine: fututre prospects of single-agent and combination studies. Oncologist 1997; 2:127-134.
14. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51:6110-6117.
15. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87:227-253.
16. Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between gemcitabine and cisplatin in vitro. Clin Cancer Res 1996; 2:521-530.
17. Van Moorsel CJA, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, et al. Mechanism of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines. Br J Cancer 1999; 80:981-990.
18. Yang LY, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 2000; 6:773-781.
19. Crul M, Schoemaker NE, Pluim D, Maliepaard M, Underberg RW, Schot M, et al. Randomized phase I clinical and pharmacologic study of weekly versus two-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003; 9:3526-3533.
20. National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, Maryland: Division of Cancer Treatment, National Cancer Institute; 1988.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
22. Ma J, Stoter G, Verweij J, Schellens JHM. Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. Cancer Chemother Pharmacol 1996; 38:391-394.
23. Van Warmerdam LJC, van Tellingen O, Maes RAA, Beijnen JH. Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fres J Anal Chem 1995; 351:1820-1824.
24. 32P-postlabelling assay for the quantification of the major platinum-DNA adducts. Anal Biochem 1999; 275:30-38.
25. Freeman KB, Anliker S, Hamilton M, Osborne D, Dhahir PH, Nelson R, et al. Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 1995; 665:171-181.
26. Sparidans RW, Crul M, Schellens JHM, Beijnen JH. Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells. J Chromatogr B Anal Technol Biomed Life Sci 2002; 780:423-430.
27. Van Zandwijk N, Smit EF, Kramer GW, Schramel F, Gans S, Festern J, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European Organization for Research and Treatment Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000; 18:2658-2664.
28. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999; 17:12-18.
29. Schellens JHM, Ma J, Planting AS, van der Burg ME, van Meerten E, de Boer-Dennert M, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumor response in patients with solid tumors. Br J Cancer 1996; 73:1569-1575.
30. Theodossiou C, Cook JA, Fisher J, Teague D, Liebmann JE, Russo A, Mitchell JB, et al. Interaction of gemcitabine and paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 1998; 12:825-832.
31. Voigt W, Bulankin A, Muller T, Schoeber C, Grothey A, Hoang-Vu C, et al. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cells. Clin Cancer Res 2000; 6:2087-2093.
32. Van Moorsel CJA, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G, et al. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumors. Eur J Cancer 2000; 36:2420-2429.